Full-Time

Senior People Systems and Data Analyst

Freenome

Freenome

201-500 employees

Blood-based multiomics cancer detection tests

Compensation Overview

$120.3k - $170.1k/yr

+ Equity + Bonus

Daly City, CA, USA

Hybrid

Category
Data & Analytics (1)
Required Skills
LLM
Power BI
Machine Learning
Human Resources Information System (HRIS)
Tableau
Data Governance
Looker
Excel/Numbers/Sheets
Requirements
  • Bachelor’s degree in Statistics, Data Science, Business Analytics, HR, Economics, or related field.
  • 5–7 years of experience in People Analytics, Workforce Analytics, HRIS Analytics, or related analytical roles.
  • Prior experience modifying, improving and/or implementing People systems (Greenhouse, Paylocity a bonus).
  • Advanced proficiency in data visualization tools (Tableau, Power BI, Looker, or similar).
  • Strong experience building executive dashboards from the ground up.
  • Knowledge of data, statistical, and predictive analysis.
  • Advanced Excel/Google Sheets skills.
  • Experience working with large, complex datasets.
  • Demonstrated ability to translate data into clear business insights and recommendations.
  • Strong understanding of core People processes (recruiting, compensation, performance, engagement, workforce planning).
  • Excellent verbal and written communication skills.
  • Strong analytical and problem-solving skills.
  • Passion for driving continuous improvement simplifying workflows, implementing automation, and driving self-service.
  • Demonstrated interest in leveraging AI to enhance systems and analytics.
Responsibilities
  • Develop, analyze, and interpret workforce data to identify trends, risks, and opportunities across recruiting, retention, performance, and engagement.
  • Conduct deep-dive analyses (attrition trends, hiring funnel performance, compensation insights, engagement drivers).
  • Build statistical and trend analyses across the employee lifecycle to proactively surface insights that influence People and business decisions.
  • Deliver actionable quarterly reporting that translates complex datasets into clear, executive-ready insights and recommendations.
  • Design, build, and maintain scalable and automated dashboards.
  • Establish consistent KPI definitions and reporting standards.
  • Improve data visualization practices to ensure clarity, usability, and impact.
  • Replace manual reporting processes with automated, real-time reporting solutions.
  • Ensure high levels of data accuracy, integrity, and trust.
  • Serve as primary People data and HRIS reporting expert.
  • Partner with IT and vendors to implement and manage integrations, evaluate new features, and identify opportunities to automate data workflows.
  • Manage data governance standards to ensure compliance and data privacy best practices.
  • Identify process improvements that enhance efficiency, data structure and accessibility.
  • Enable tier-zero employee and manager self-service for policies, processes, and data through systems and chatbots, reducing reliance on People team members and ticket systems.
  • Champion system education to drive employee and manager self-service adoption and data and systems utilization.
  • Drive AI initiatives such as deploying LLMs for job descriptions and ML to forecast attrition, ensuring tools are trained and continuously refined to be fit-for-purpose and remain within ethical and legal guardrails.
Desired Qualifications
  • Experience in a high-growth biotech or startup environment, with exposure to IPO preparation, public company reporting requirements, or SOX-compliant processes.
  • Familiarity with Greenhouse, Paylocity, or other HRIS/ATS platforms.
  • Exposure to predictive analytics or basic modeling techniques.
  • SHRM-CP or SHRM-SCP certification.

Freenome develops non-invasive blood tests for early cancer detection by combining genomics and proteomics to identify cancer signals in blood. The tests are sold to healthcare providers and research institutions and are also used in clinical trials and collaborations. The process involves analyzing a blood sample with proprietary algorithms to assess cancer risk and guide follow-up diagnostics. By integrating multiple data types and pursuing large-scale trials, Freenome aims to make early cancer screening routine and improve patient outcomes, with a focus on expanding colorectal cancer testing.

Company Size

201-500

Company Stage

Late Stage VC

Total Funding

$1.1B

Headquarters

San Francisco, California

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • SimpleScreen CRC FDA approval expected H2 2026 unlocks $2B+ colorectal cancer screening market.
  • SPAC merger with Perceptive Capital Solutions provides $330M funding for multi-cancer pipeline expansion.
  • Roche $75M investment and $200M+ deal validates technology and accelerates global commercialization.

What critics are saying

  • Exact Sciences exclusive U.S. rights eliminate Freenome's domestic revenue and commercialization control.
  • SPAC merger failure depletes cash reserves after 100-employee layoffs, halting product launches.
  • Guardant Health's Shield test captures 70% market share, undercutting Freenome's multiomics platform.

What makes Freenome unique

  • Multiomics platform analyzes DNA, immune, and metabolic signals for earliest cancer detection.
  • Secured exclusive U.S. colorectal cancer rights deal with Exact Sciences worth up to $775 million.
  • Roche partnership enables kitted decentralized testing and Axelios sequencing technology evaluation internationally.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Freenome who can refer or advise you

Benefits

Competitive market-based salaries

Annual bonus opportunities

Relocation packages

Medical, dental, & vision coverage

401k

Wellness programs

Equity

PTO

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

0%

2 year growth

-3%
BioPharma Dive
Nov 20th, 2025
Roche inks deal for rights to Freenome cancer tests outside US

Roche inks deal for rights to Freenome cancer tests outside US. Roche is investing $75 million in Freenome as part of the deal, which comes a year after the Swiss company led a $254 million financing round. Dive brief: * Roche has struck a deal to commercialize Freenome's cancer screening technology outside the U.S., the companies said Tuesday. * Freenome will receive a $75 million investment from Roche as part of a deal that could be worth more than $200 million. * The deal positions Freenome, which currently uses Illumina machines, to evaluate Roche's new sequencing device. In a note to clients, Leerink Partners analysts said they see no near- to medium-term impact on Illumina. Dive insight: Nearing pre-market approval of its colorectal cancer blood-based screening test, Freenome has struck deals to support its commercialization in recent months. In August, Exact Sciences agreed to pay Freenome $75 million upfront, plus up to $700 million in milestones, for U.S. rights to current and future versions of the test. Roche's deal covers the marketing of "kitted" tests in areas outside of the U.S. Kitted tests package the software and assay to enable decentralized test processing and analysis, eliminating the need for a singular large processing lab. Freenome has retained rights to centralized testing outside the U.S. Roche, meanwhile, could shell out milestone payments and royalties on ex-U.S. sales. The $75 million equity investment increases Roche's stake in Freenome after leading a $254 million financing round last year. Other Roche investments, such as positions backing Flatiron Health and Foundation Medicine, have resulted in acquisitions. Freenome already uses Roche's Elecsys technology for multiple types of analyses. Under the new deal, Freenome will study the potential for Roche's "sequencing by expansion" technology to enhance its cell-free DNA cancer screening tests. Freenome will also gain access to Roche plasma sample cohorts to support the development of personalized screening tests for multiple types of cancer. Roche unveiled its sequencing technology in February and provided more information at its diagnostics day in May. At that event, Josh Lauer, the company's head of molecular labs, said "speed is something very unique about this platform and something no other short-read sequencer is able to match." Leerink analysts evaluated the threat the technology - which Roche has branded Axelios - poses to Illumina in light of the Freenome agreement. The analysts said the deal "highlights Roche's long-term strategy for Axelios - a clinical box for running NGS kits, similar to with their prior success in IVD kits." Yet it will take a few years of testing and refinement to ready Axelios for clinical sequencing, they added. "We don't expect other oncology Dx companies to jump to try Roche SBX in [the] U.S. or internationally given their new assays are already entrenched and some are FDA approved on [Illumina] sequencers," the analysts said in a note to investors. "Switching costs and reliability needs are high and clinical Dx companies indicate they won't entertain the switch without a clear value proposition."

Freenome
Nov 19th, 2025
Freenome Announces Exclusive Agreement with Roche to Expand Technology Collaboration and Develop and Commercialize Cancer Screening Tests Outside the U.S.

– Partnership focuses on “kitted” tests in ex-U.S. markets, enabling accelerated access through a decentralized model – – Deal potentially […]

finanzen.net
Nov 18th, 2025
Freenome, Roche Partner in $200M Deal

Freenome has partnered with Roche in a deal potentially worth over $200 million to commercialize its cancer screening technology in international markets. The agreement includes a $75 million equity investment from Roche and focuses on developing "kitted" tests for decentralized processing. Freenome will also evaluate Roche's Sequencing by Expansion technology. This collaboration aims to enhance Freenome's multiomic blood-based cancer screening platform and expand its global reach.

PR Newswire
Jun 2nd, 2025
Freenome Announces Jama Publication Of Data From Pivotal Study Of Its Blood-Based Test For Colorectal Cancer

– PREEMPT CRC, the largest prospective study of its kind, met all primary efficacy endpoints and surpassed CMS coverage requirements for sensitivity and specificity in the intended use population –. – FDA premarket approval submission is underway, with completion anticipated mid-2025 –. BRISBANE, Calif., June 2, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the publication of detailed results from the pivotal PREEMPT CRC study in JAMA.1 The publication presents findings from the largest prospective study of a blood-based screening test for colorectal cancer (CRC), involving 48,995 average-risk adults aged 45 to 85 who underwent a routine colonoscopy following a blood draw

Health Technology Insights
May 21st, 2025
Freenome Appoints Linh H. Le as Chief Financial Officer

Freenome appoints Linh H. Le as chief financial officer.